Anas Younes, M.D. (@dranasyounes) 's Twitter Profile
Anas Younes, M.D.

@dranasyounes

Medical oncologist/scientist. Former Chief of Lymphoma at MSKCC. Working on changing treatment outcome for patients with blood cancers. Now SVP at AstraZeneca.

ID: 23631835

calendar_today10-03-2009 18:48:37

24,24K Tweet

18,18K Followers

380 Following

Anas Younes, M.D. (@dranasyounes) 's Twitter Profile Photo

BAYREUTH REELS FROM WORST-EVER BOOING: When the curtain fell on the new production... Source: Slippedisc search.app/qz3geaMuP3RWqi…

Tatiana Prowell, MD (@tmprowell) 's Twitter Profile Photo

NEW 📣Final FDA Guidance on decentralized #clinicaltrials is out! Covers local labs, imaging, procedures; local healthcare providers; telehealth; informed consent; inv product delivery/accountability; & data mgmt. #MedTwitter #regulatory #DrugDevelopment fda.gov/regulatory-inf…

Anas Younes, M.D. (@dranasyounes) 's Twitter Profile Photo

An impressive art installation in Manhattan's Meatpacking District depicting 100 life-sized elephants. The "Great Elephant Migration" is one of the largest outdoor installations ever in New York

An impressive art installation in Manhattan's Meatpacking District depicting 100 life-sized elephants. The "Great Elephant Migration" is one of the largest outdoor installations ever in New York
Anas Younes, M.D. (@dranasyounes) 's Twitter Profile Photo

Amazing performance of “the Marriage of Figaro “ by Anthony Roth Costanzo at Little Island amphitheater, as he sang every leading role in the opera!

Anas Younes, M.D. (@dranasyounes) 's Twitter Profile Photo

Innovative medicines and novel combination regimens significantly changed PFS and OS of patients with multiple myeloma over the past 2 decades. And the recent endorsement of using MRD as an intermediate endpoint, will certainly accelerate bringing new therapies to patients #IMS24

Innovative medicines and novel combination regimens significantly changed PFS and OS of patients with multiple myeloma over the past 2 decades. And the recent endorsement of using MRD as an intermediate endpoint, will certainly accelerate bringing new therapies to patients #IMS24